GREY:ICOTF - Post by User
Post by
gainwidpatienceon Jul 13, 2018 8:50am
98 Views
Post# 28311033
How Wuxi and IMNP deal benefited ICO?
How Wuxi and IMNP deal benefited ICO?iCo may receive up to an additional US$32 million in milestone payments as well as royalties on net sales of licensed products.
Non ocular uses of the drug may include asthma and prevalent inflammatory bowel conditions. iCo will retain worldwide exclusive rights to all uses and applications in the ocular field. iCo estimates the market for ocular applications, including age-related macular degeneration and sight-threatening ocular allergies exceeds $2 billion.